Virtu Financial LLC Makes New Investment in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)

Virtu Financial LLC bought a new position in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,803 shares of the biotechnology company’s stock, valued at approximately $246,000.

Several other hedge funds have also recently bought and sold shares of the business. Pacific Capital Wealth Advisors Inc. bought a new stake in Cerevel Therapeutics during the fourth quarter valued at about $71,000. PNC Financial Services Group Inc. boosted its holdings in Cerevel Therapeutics by 68.5% during the third quarter. PNC Financial Services Group Inc. now owns 9,506 shares of the biotechnology company’s stock valued at $208,000 after acquiring an additional 3,866 shares during the period. GAM Holding AG bought a new stake in Cerevel Therapeutics during the fourth quarter valued at about $212,000. Dark Forest Capital Management LP bought a new stake in Cerevel Therapeutics during the third quarter valued at about $267,000. Finally, Trexquant Investment LP bought a new stake in Cerevel Therapeutics during the third quarter valued at about $314,000. 87.73% of the stock is owned by institutional investors and hedge funds.

Cerevel Therapeutics Stock Down 0.1 %

CERE stock opened at $41.65 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 10.22 and a quick ratio of 10.22. Cerevel Therapeutics Holdings, Inc. has a 52-week low of $19.59 and a 52-week high of $43.59. The company has a 50-day moving average of $41.68 and a two-hundred day moving average of $41.72. The stock has a market capitalization of $7.59 billion, a price-to-earnings ratio of -15.26 and a beta of 1.41.

Cerevel Therapeutics (NASDAQ:CERE) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.12). As a group, equities research analysts anticipate that Cerevel Therapeutics Holdings, Inc. will post -2.63 EPS for the current year.

Insider Activity at Cerevel Therapeutics

In related news, Director N Anthony Coles sold 50,000 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $42.10, for a total value of $2,105,000.00. Following the completion of the sale, the director now owns 15,638 shares in the company, valued at $658,359.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 5.10% of the stock is owned by corporate insiders.

Cerevel Therapeutics Company Profile

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.